7-(4-hydroxy-3-methoxybenzoyl)oxyheptyl-4-hydroxy-3-methoxybenzoate | 1222380-60-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 7-(4-hydroxy-3-methoxybenzoyl)oxyheptyl-4-hydroxy-3-methoxybenzoate
• 英文别名: 7-(4-hydroxy-3-methoxy-benzoyl)oxyheptyl 4-hydroxy-3-methoxy-benzoate；7-(4-Hydroxy-3-methoxybenzoyl)oxyheptyl 4-hydroxy-3-methoxybenzoate
• CAS: 1222380-60-0
• 化学式: C₂₃H₂₈O₈
• 分子量: 432.471
• InChiKey: LCXOWQVFSXNYSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  31
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1,7-二溴庚烷 、 香草酸 在 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以44%的产率得到7-(4-hydroxy-3-methoxybenzoyl)oxyheptyl-4-hydroxy-3-methoxybenzoate
  参考文献：
  名称：

  Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli

  摘要：

  A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC50 growth inhibitory ones, accounting, at least partly, for their cytostatic effects in cancer cells and to a lesser extent in normal cells. Compounds 6b and 13c represent interesting starting points for the development of cytostatic agents to combat cancers, which are naturally resistant to pro-apoptotic stimuli, including metastatic malignancies. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.04.047

文献信息

• [EN] DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY<br/>[FR] DÉRIVÉS DE DI-VANILLOYLE ET DE TRI-VANILLOYLE POUR UNE UTILISATION DANS UNE THÉRAPIE ANTI-CANCÉREUSE
  申请人：UNIV BRUXELLES

  公开号：WO2010043631A1

  公开（公告）日：2010-04-22

  The invention relates to the medical field, more precisely in the field of anti-cancer treatment and treatment of Alzheimer's disease, Parkinson's disease or Pick's disease or for ameliorating symptoms of Down syndrome, providing newly synthesised multi-vanilloyl derivative compounds and their use in the treatment of said disorders.

  这项发明涉及医学领域，更准确地说是在抗癌治疗和治疗阿尔茨海默病、帕金森病或皮克氏病，或改善唐氏综合征症状方面，提供新合成的多香豆酰衍生物化合物及其在治疗上述疾病中的用途。
• Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy
  申请人：Kiss Robert

  公开号：US20110280940A1

  公开（公告）日：2011-11-17

  The invention relates to the medical field, more precisely in the field of anti-cancer treatment and treatment of Alzheimer's disease, Parkinson's disease or Pick's disease or for ameliorating symptoms of Down syndrome, providing newly synthesised multi-vanilloyl derivative compounds and their use in the treatment of said disorders.

  该发明涉及医学领域，更精确地说是抗癌治疗和治疗阿尔茨海默病、帕金森病或皮克氏病或改善唐氏综合症症状的领域，提供新合成的多香豆酰衍生物化合物及其在治疗上述疾病中的应用。
• DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY
  申请人：Université Libre de Bruxelles

  公开号：EP2367545A1

  公开（公告）日：2011-09-28
• METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
  申请人：Design Therapeutics, Inc.

  公开号：US20210238226A1

  公开（公告）日：2021-08-05

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, atxn1, atxn2, atxn3, cacna1a, atxn7, ppp2r2br tbp, htt, jph3r ar, or atn1 and treating diseases and conditions in which dmpk, atxn1, atxn2, atxn3, cacna1a, atxn1, ppp2r2b, tbp, htt, jph3, ar, or atn1 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
• Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli
  作者：Delphine Lamoral-Theys、Laurent Pottier、Frédéric Kerff、François Dufrasne、Fabien Proutière、Nathalie Wauthoz、Philippe Neven、Laurent Ingrassia、Pierre Van Antwerpen、Florence Lefranc

  DOI：10.1016/j.bmc.2010.04.047

  日期：2010.6.1

  A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC50 growth inhibitory ones, accounting, at least partly, for their cytostatic effects in cancer cells and to a lesser extent in normal cells. Compounds 6b and 13c represent interesting starting points for the development of cytostatic agents to combat cancers, which are naturally resistant to pro-apoptotic stimuli, including metastatic malignancies. (C) 2010 Elsevier Ltd. All rights reserved.